| P50 | author | Susan Clark | Q42658558 |
| P2093 | author name string | F Valdés-Mora | |
| P2860 | cites work | Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates | Q21089989 |
| | Translating the Histone Code | Q22065840 |
| | The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain | Q22065852 |
| | Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2 | Q24306181 |
| | Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1 | Q24316558 |
| | Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers | Q24605342 |
| | Genome-scale DNA methylation maps of pluripotent and differentiated cells | Q24621431 |
| | High sensitivity mapping of methylated cytosines | Q24630600 |
| | Human DNA methylomes at base resolution show widespread epigenomic differences | Q24633677 |
| | Circulating microRNAs as stable blood-based markers for cancer detection | Q24652098 |
| | Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation | Q26823896 |
| | Global levels of histone modifications predict prostate cancer recurrence. | Q39899696 |
| | DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. | Q39923092 |
| | MicroRNA profile analysis of human prostate cancers | Q39925866 |
| | A polycomb repression signature in metastatic prostate cancer predicts cancer outcome | Q40050697 |
| | Androgen deprivation increases p300 expression in prostate cancer cells | Q40149224 |
| | Genome-scale DNA methylation mapping of clinical samples at single-nucleotide resolution | Q40222806 |
| | Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. | Q40414404 |
| | The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer | Q40513860 |
| | Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development | Q40651903 |
| | Comprehensive high-throughput arrays for relative methylation (CHARM). | Q42155651 |
| | Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease | Q43007431 |
| | Evidence linking CD44-positive cells and gemcitabine resistance in pancreatic cancer cells: need for further substantiation | Q43251963 |
| | Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development | Q43607238 |
| | A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy | Q43627769 |
| | DNA-based detection of prostate cancer in urine after prostatic massage | Q43732285 |
| | Molecular detection of prostate cancer in urine by GSTP1 hypermethylation | Q43736426 |
| | Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer | Q44244665 |
| | Global histone modification patterns predict risk of prostate cancer recurrence | Q46162501 |
| | Multigene methylation analysis for detection and staging of prostate cancer | Q46335820 |
| | Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy | Q46522673 |
| | Dynamic readers for 5-(hydroxy)methylcytosine and its oxidized derivatives | Q48151931 |
| | Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. | Q52968193 |
| | CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. | Q53324496 |
| | Regional loss of imprinting of the insulin-like growth factor II gene occurs in human prostate tissues. | Q53459153 |
| | Epigenetics of prostate cancer: distribution of histone H3K27me3 biomarkers in peri-tumoral tissue. | Q54223274 |
| | High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. | Q54432522 |
| | Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. | Q54642524 |
| | Hypermethylation of CpG islands in primary and metastatic human prostate cancer. | Q54725480 |
| | Histone macroH2A isoforms predict the risk of lung cancer recurrence | Q57263888 |
| | Molecular Detection of Localized Prostate Cancer Using Quantitative Methylation-Specific PCR on Urinary Cells Obtained Following Prostate Massage | Q57565212 |
| | DNA methylation: Bisulphite modification and analysis | Q61283947 |
| | Global histone H3K27 methylation levels are different in localized and metastatic prostate cancer | Q63979896 |
| | Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications | Q71870897 |
| | Detailed methylation analysis of the glutathione S-transferase pi (GSTP1) gene in prostate cancer | Q74450233 |
| | High throughput screening of methylation status of genes in prostate cancer using an oligonucleotide methylation array | Q80865904 |
| | EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients | Q81456373 |
| | CD44 and PTGS2 methylation are independent prognostic markers for biochemical recurrence among prostate cancer patients with clinically localized disease | Q81590992 |
| | Histone H2A.Z prepares the prostate specific antigen (PSA) gene for androgen receptor-mediated transcription and is upregulated in a model of prostate cancer progression | Q82357114 |
| | Evaluation of the Infinium Methylation 450K technology | Q82726350 |
| | Circulating miRNAs are correlated with tumor progression in prostate cancer | Q84232903 |
| | Evaluation of global DNA hypomethylation in human prostate cancer and prostatic intraepithelial neoplasm tissues by immunohistochemistry | Q84444815 |
| | Finding the true $1000 genome | Q86065380 |
| | miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions | Q95780206 |
| | Widespread deregulation of microRNA expression in human prostate cancer. | Q38297946 |
| | Predicting prostate biopsy result in men with prostate specific antigen 2.0 to 10.0 ng/ml using an investigational prostate cancer methylation assay | Q38436902 |
| | Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome? | Q38444915 |
| | Genomic hypomethylation and CpG island hypermethylation in prostatic intraepithelial neoplasm | Q38497589 |
| | Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. | Q38507846 |
| | The Promise and the Problems of Epigenetics Biomarkers in Cancer | Q38681923 |
| | Regional activation of the cancer genome by long-range epigenetic remodeling | Q39225111 |
| | Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer | Q39301447 |
| | Global levels of H3K27me3 track with differentiation in vivo and are deregulated by MYC in prostate cancer. | Q39328341 |
| | Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains | Q39436834 |
| | Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer | Q39505285 |
| | Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome | Q39540112 |
| | DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer | Q39552467 |
| | Quantitative comparison of genome-wide DNA methylation mapping technologies. | Q39654059 |
| | Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. | Q39654624 |
| | The chromatin remodeling factor SRCAP modulates expression of prostate specific antigen and cellular proliferation in prostate cancer cells | Q39708948 |
| | MBD-isolated Genome Sequencing provides a high-throughput and comprehensive survey of DNA methylation in the human genome | Q39776070 |
| | Sequencing technologies - the next generation | Q27860568 |
| | High-resolution profiling of histone methylations in the human genome | Q27860906 |
| | Cancer statistics, 2014 | Q27861018 |
| | DNA methylation: a profile of methods and applications | Q28202469 |
| | Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer | Q28239595 |
| | The new date, new format, new goals and new sponsor of the Archon Genomics X PRIZE competition | Q28251506 |
| | Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma | Q28254781 |
| | Quantitative sequencing of 5-methylcytosine and 5-hydroxymethylcytosine at single-base resolution | Q28265420 |
| | Histone variants--ancient wrap artists of the epigenome | Q28274796 |
| | Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence | Q28277232 |
| | The epigenomics of cancer | Q28289975 |
| | Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis | Q28298213 |
| | Judging the Archon Genomics X PRIZE for whole human genome sequencing | Q28306089 |
| | Reprogramming of the paternal genome upon fertilization involves genome-wide oxidation of 5-methylcytosine | Q28585429 |
| | 5-Hydroxymethylcytosine in the mammalian zygote is linked with epigenetic reprogramming | Q28588147 |
| | The polycomb group protein EZH2 is involved in progression of prostate cancer | Q29614514 |
| | Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells | Q29618090 |
| | RNA sequencing: advances, challenges and opportunities | Q29619605 |
| | EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent | Q30538848 |
| | Genomic profiling of CpG methylation and allelic specificity using quantitative high-throughput mass spectrometry: critical evaluation and improvements | Q33298863 |
| | miRNA analysis of prostate cancer by quantitative real time PCR: comparison between formalin-fixed paraffin embedded and fresh-frozen tissue. | Q33500521 |
| | Histone variants: emerging players in cancer biology | Q33630867 |
| | Immunohistochemistry as an important tool in biomarkers detection and clinical practice | Q33704442 |
| | Evaluation of affinity-based genome-wide DNA methylation data: effects of CpG density, amplification bias, and copy number variation | Q33736481 |
| | Epigenetic deregulation across chromosome 2q14.2 differentiates normal from prostate cancer and provides a regional panel of novel DNA methylation cancer biomarkers. | Q33753677 |
| | Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer | Q33949373 |
| | New strategies in prostate cancer: translating genomics into the clinic | Q34007943 |
| | Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force | Q34044753 |
| | Principles and challenges of genomewide DNA methylation analysis | Q34096366 |
| | Genomic distribution and inter-sample variation of non-CpG methylation across human cell types | Q34102774 |
| | Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer | Q34115910 |
| | Interrogating genomic and epigenomic data to understand prostate cancer | Q34125866 |
| | Comparison of sequencing-based methods to profile DNA methylation and identification of monoallelic epigenetic modifications. | Q34138823 |
| | Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine | Q34154619 |
| | TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia | Q34157339 |
| | Dynamic stage-specific changes in imprinted differentially methylated regions during early mammalian development and prevalence of non-CpG methylation in oocytes | Q34159815 |
| | Cell-free nucleic acids as biomarkers in cancer patients | Q34184393 |
| | Alterations of global histone H4K20 methylation during prostate carcinogenesis | Q34194181 |
| | Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation | Q34258768 |
| | TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases | Q34301250 |
| | In vivo control of CpG and non-CpG DNA methylation by DNA methyltransferases | Q34325535 |
| | Perspectives of international human epigenome consortium | Q34341033 |
| | GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer | Q34544893 |
| | Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (LRES) reduces transcriptional plasticity | Q34680105 |
| | USP10 deubiquitylates the histone variant H2A.Z and both are required for androgen receptor-mediated gene activation | Q34947175 |
| | Focused, high accuracy 5-methylcytosine quantitation with base resolution by benchtop next-generation sequencing | Q35054319 |
| | Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression | Q35154249 |
| | Cancer epigenetics: linking basic biology to clinical medicine. | Q35348043 |
| | 5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations | Q35624365 |
| | Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. | Q35640316 |
| | Acetylation of H2A.Z is a key epigenetic modification associated with gene deregulation and epigenetic remodeling in cancer | Q35694399 |
| | Changes in circulating microRNA levels associated with prostate cancer | Q35879858 |
| | Epigenetic deregulation of miR-29a and miR-1256 by isoflavone contributes to the inhibition of prostate cancer cell growth and invasion | Q36187865 |
| | Base-resolution analysis of 5-hydroxymethylcytosine in the mammalian genome. | Q36659158 |
| | Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression | Q36671809 |
| | Epigenomic alterations in localized and advanced prostate cancer | Q36730577 |
| | ENCODE: A Sourcebook of Epigenomes and Chromatin Language | Q36778458 |
| | Punctuated evolution of prostate cancer genomes | Q36950514 |
| | Differential regulation and predictive potential of MacroH2A1 isoforms in colon cancer | Q37030875 |
| | Beyond PSA: the next generation of prostate cancer biomarkers | Q37238101 |
| | DNA methylomes, histone codes and miRNAs: tying it all together | Q37286430 |
| | Clinical relevance of circulating nucleosomes in cancer. | Q37287952 |
| | Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context | Q37288832 |
| | Insulin-like growth factor-2 (IGF2) loss of imprinting marks a field defect within human prostates containing cancer | Q37301123 |
| | Epigenetics in prostate cancer: biologic and clinical relevance | Q37896315 |
| | The epigenetic promise for prostate cancer diagnosis | Q37967574 |
| | Next-generation sequencing: ready for the clinics? | Q37989166 |
| | Metastatic castrate-resistant prostate cancer: dawn of a new age of management | Q38008050 |
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| | biomarker | Q864574 |
| P304 | page(s) | 1609-1618 | |
| P577 | publication date | 2014-05-19 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | Prostate cancer epigenetic biomarkers: next-generation technologies | |
| P478 | volume | 34 | |